Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 13
Treatment-assignment count: 0
Stratification count: 0
Drug Development Ahead Of Cdx Context
ALK fusion
breast cancer · Monoclonal Antibody
ALK fusion is flagged as drug development ahead of cdx context because public trials show inclusion required evidence in 15 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: Medium
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT00932373 | https://clinicaltrials.gov/study/NCT01594177 | https://clinicaltrials.gov/study/NCT01937117 | https://clinicaltrials.gov/study/NCT00493649 | https://clinicaltrials.gov/study/NCT01763710 | https://clinicaltrials.gov/study/NCT00436566 | https://clinicaltrials.gov/study/NCT01472146 | https://clinicaltrials.gov/study/NCT01973660 | https://clinicaltrials.gov/study/NCT02624973 | https://clinicaltrials.gov/study/NCT00949247 | https://clinicaltrials.gov/study/NCT03379428 | https://clinicaltrials.gov/study/NCT00317720 | https://clinicaltrials.gov/study/NCT01534455 | https://clinicaltrials.gov/study/NCT01306942 | https://clinicaltrials.gov/study/NCT02996825